

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 September 2017 (14.09.2017)



(10) International Publication Number
WO 2017/156511 A8

(51) International Patent Classification:
A61K 39/12 (2006.01)

(21) International Application Number:

PCT/US2017/021989

(22) International Filing Date:

11 March 2017 (11.03.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/307,170

11 March 2016 (11.03.2016)

US

(71) Applicants: **THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES** [US/US]; National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325,

MSC 7660, Bethesda, MD 20892-7660 (US). **THE JOHNS HOPKINS UNIVERSITY** [US/US]; 3400 N. Charles Street, Baltimore, MD 21218 (US).


(72) Inventors: **WHITEHEAD, Stephen, S.**; 9644 Duffer Way, Montgomery Village, MD 20886 (US). **WOODSON, Sara, E.**; 3307 Glenway Drive, Kensington, MD 20895 (US). **DURBIN, Anna, P.**; 806 Hudson Ave., Takoma Park, MD 20912 (US). **PLETNEV, Alexander, G.**; 31 Inkberry Circle, Gaithersburg, MD 20877 (US). **TSETTSARKIN, Konstantin, A.**; 18304 Swan Stream Drive, Gaithersburg, MD 20877 (US).

(74) Agent: **GRAF, Susan W.** et al.; Klarquist Sparkman LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: LIVE ATTENUATED ZIKA VIRUS VACCINE

FIG. 1A
(prior art)



(57) **Abstract:** The present disclosure relates to attenuated Zika viruses and vaccines, attenuated chimeric Zika viruses and vaccines, and to multivalent immunogenic compositions comprising Zika vaccines and vaccines to other flaviviruses. The chimeric Zika viruses includes a first nucleotide sequence encoding at least one structural protein from a Zika virus (ZIKV), a second nucleotide sequence encoding at least one nonstructural protein from a first flavivirus, and a third nucleotide sequence of a (3') untranslated region from a second flavivirus. The multivalent immunogenic compositions comprise an attenuated ZIKV vaccine or an attenuated chimeric ZIKV vaccine (or their combination) together with one or more of a first attenuated virus that is immunogenic against dengue serotype (1), a second attenuated virus that is immunogenic against dengue serotype (2), a third attenuated virus that is immunogenic against dengue serotype (3), and a fourth attenuated virus that is immunogenic against dengue serotype (4). The present disclosure further relates to methods of inducing immune responses, as well as preventing or treating ZIKV infections, and in certain embodiments, the combined prevention or treatment of ZIKV and another flavivirus, e.g., dengue virus.

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR,
KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

27 September 2018 (27.09.2018)

(15) Information about Correction:

see Notice of 27 September 2018 (27.09.2018)